Alrestatin (sodium) - CAS 51876-97-2
Catalog number: 51876-97-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Aldose Reductase
Alrestatin sodium is a specific inhibitor of aldose reductase (IC50 = 148 μM).
White crystalline solid
Soluble in DMSO
Store at -20 °C
A specific inhibitor of aldose reductase
Quality Standard:
Enterprise Standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Melting Point:
262 - 265 °C
Canonical SMILES:
Current Developer:
1.Alrestatin: gastric acid antisecretory-antiulcer activity in the rat.
Lippmann W;Seethaler K;Borella LE;Pugsley TA Digestion. 1978;18(1-2):35-44.
Alrestatin sodium (AY-22,284-A) inhibited gastric acid secretion and decreased the volume of gastric juice produced in the pylorus-ligated rat when administered intraperitoneally or perorally. Pentagastrin-induced gastric acid output in the unanesthetized rat was antagonized. The pyloric ligation-induced ulcer formation in the rat was inhibited. Alrestatin sodium did not exhibit an anticholinergic profile. The drug did not block the norepinephrine neuronal uptake mechanism in rat brain or heart; it did not alter the endogenous norepinephrine concentration in the heart and decreased endogeneous brain norepinephrine concentration. Alrestatin sodium is an effective inhibitor of gastric acid secretion and ulcer formation in the rat.
2.Effect of alrestatin sodium on glucose-stimulated insulin secretion in the fasted anaesthetized rat.
Kobric M;Lippmann W Horm Metab Res. 1978 Nov;10(6):495-500.
In the anaesthetized fasted non-diabetic male intact rat, alrestatin sodium injected as a bolus (0.75 mmol/kg, i.v.) did not affect basal plasma insulin or glucose levels. However, in response to an intravenous glucose tolerance test, plasma insulin levels were significantly increased above the values observed in the animal during a control test. The decreases in plasma glucose levels after alrestatin were significantly greater than in the control study. In rat pancreatic preparations in vitro, alrestatin lowered the basal release of 3H-norepinephrine and also the release obtained with the catecholamine-releasing agent tyramine. A modulation of catecholamine release appears to be of importance in the mode of action of alrestatin with respect to the insulin secretion and plasma glucose levels. It is suggested that alrestatin may play a useful role in the therapy of diabetes mellitus since it can augment insulin secretion when glucose is administered to a fasted animal in which the acute insulin response has been shown to be like that of the human diabetic, and in addition, can lower arginine-stimulated glucagon secretion in the animal, the latter being a model of an action that is observed in the human diabetic.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Aldose Reductase Products

CAS 105346-34-7 FR-62765

(CAS: 105346-34-7)

FR-62765, a derivative of WF-3681, is a novel aldose reductase inhibitor. It might be a useful drug for diabetic neuropathy.

CAS 51411-04-2 Alrestatin

(CAS: 51411-04-2)

Alrestatin is an inhibitor of aldose reductase (IC50 = 148 μM).

CAS 82964-04-3 Tolrestat

(CAS: 82964-04-3)

Tolrestat is an orally active and potent aldose reductase inhibitor with IC50 value of 35 nM. It was approved for the control of certain diabetic complications....

CAS 82159-09-9 Epalrestat

(CAS: 82159-09-9)

Epalrestat is an aldose reductase inhibitor with IC50 of 72 nM.

CAS 4450-98-0 EBPC

(CAS: 4450-98-0)

EBPC is a potent and selective aldose reductase inhibitor. It is used to improve the cytotoxicity of anticancer reagents such as cisplatin and doxorubicin in He...

CAS 51876-97-2 Alrestatin (sodium)

Alrestatin (sodium)
(CAS: 51876-97-2)

Alrestatin sodium is a specific inhibitor of aldose reductase (IC50 = 148 μM).

CAS 110703-94-1 Zopolrestat

(CAS: 110703-94-1)

Zopolrestat is an inhibitor of Aldose Reductase(AR). It has been shown to play roles in inflammation and cancer. It is used for the treatment of diabetic nephro...

CAS 147254-64-6 Raniestat

(CAS: 147254-64-6)

Raniestat, a highly potent aldose reductase inhibitor currently under phase III clinical trials in the US and Canada, is used to treat diabetic neuropathies.

Chemical Structure

CAS 51876-97-2 Alrestatin (sodium)

Quick Inquiry

Verification code

Featured Items